Literature DB >> 25941592

Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein.

Liang Cheng1, Xuexiang Du2, Lishan Su1, Shengdian Wang3.   

Abstract

Liver cancer has a poor prognosis. Our recent study demonstrates that hyper-IL-15, composed of IL-15 and the sushi domain of IL-15 receptor α chain, provides an effective therapy against well-established metastatic and autochthonous liver cancers in mouse models by triggering activation and expansion of hepatic CD8+ T cells.

Entities:  

Keywords:  CD8+ T cell; IFNγ; hyper-IL-15; immunotherapy; liver cancer

Year:  2014        PMID： 25941592      PMCID： PMC4292759          DOI： 10.4161/21624011.2014.963409

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells.

Authors:  Sigrid Dubois; Jennifer Mariner; Thomas A Waldmann; Yutaka Tagaya
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

Review 3.  The liver as a lymphoid organ.

Authors:  Ian Nicholas Crispe
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

4.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 6.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.

Authors:  Thomas A Waldmann
Journal:  Nat Rev Immunol       Date:  2006-08       Impact factor: 53.106

7.  Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Authors:  Mathieu Epardaud; Kutlu G Elpek; Mark P Rubinstein; Ai-ris Yonekura; Angelique Bellemare-Pelletier; Roderick Bronson; Jessica A Hamerman; Ananda W Goldrath; Shannon J Turley
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

8.  Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses.

Authors:  Liang Cheng; Xuexiang Du; Zheng Wang; Jianqi Ju; Mingming Jia; Qibin Huang; Qiao Xing; Meng Xu; Yi Tan; Mingyue Liu; Peishuang Du; Lishan Su; Shengdian Wang
Journal:  J Hepatol       Date:  2014-07-10       Impact factor: 25.083

9.  Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.

Authors:  Ryan M Teague; Blythe D Sather; Jilian A Sacks; Maria Z Huang; Michelle L Dossett; Junko Morimoto; Xiaoxio Tan; Susan E Sutton; Michael P Cooke; Claes Ohlén; Philip D Greenberg
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440
  9 in total
  1 in total

1.  S-15 in combination of Akt inhibitor promotes the expansion of CD45RA-CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells.

Authors:  Benling Xu; Long Yuan; Guangyu Chen; Tiepeng Li; Jinxue Zhou; Chengjuan Zhang; Peng Qin; Musleh M Muthana; Shengdian Wang; Xuexiang Du; Quanli Gao
Journal:  Cancer Cell Int       Date:  2019-12-03       Impact factor: 5.722
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.